- Home
- BLNK vs QNCX Comparison
BLNK vs QNCX Comparison
Compare BLNK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- QNCX
- Stock Information
- Founded
- BLNK 2009
- QNCX 2012
- Country
- BLNK United States
- QNCX United States
- Employees
- BLNK N/A
- QNCX N/A
- Industry
- BLNK Industrial Specialties
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLNK Consumer Discretionary
- QNCX Health Care
- Exchange
- BLNK Nasdaq
- QNCX Nasdaq
- Market Cap
- BLNK 100.0M
- QNCX 90.8M
- IPO Year
- BLNK N/A
- QNCX 2019
- Fundamental
- Price
- BLNK $0.94
- QNCX $1.69
- Analyst Decision
- BLNK Buy
- QNCX Strong Buy
- Analyst Count
- BLNK 8
- QNCX 6
- Target Price
- BLNK $2.54
- QNCX $8.00
- AVG Volume (30 Days)
- BLNK 2.4M
- QNCX 216.9K
- Earning Date
- BLNK 08-18-2025
- QNCX 08-11-2025
- Dividend Yield
- BLNK N/A
- QNCX N/A
- EPS Growth
- BLNK N/A
- QNCX N/A
- EPS
- BLNK N/A
- QNCX N/A
- Revenue
- BLNK $109,383,000.00
- QNCX N/A
- Revenue This Year
- BLNK N/A
- QNCX N/A
- Revenue Next Year
- BLNK $33.41
- QNCX N/A
- P/E Ratio
- BLNK N/A
- QNCX N/A
- Revenue Growth
- BLNK N/A
- QNCX N/A
- 52 Week Low
- BLNK $0.63
- QNCX $0.51
- 52 Week High
- BLNK $2.32
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- BLNK 47.63
- QNCX 50.81
- Support Level
- BLNK $0.90
- QNCX $1.53
- Resistance Level
- BLNK $0.96
- QNCX $1.93
- Average True Range (ATR)
- BLNK 0.05
- QNCX 0.14
- MACD
- BLNK -0.01
- QNCX -0.01
- Stochastic Oscillator
- BLNK 47.67
- QNCX 40.00
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.